Eigen Therapeutics
Kamran A. started their work experience in 2009 as a Research Associate at the University of California, San Francisco. Kamran then moved on to become a Graduate Student Researcher at UC Irvine in 2010, where they worked on research in Mammalian Synthetic Biology and Directed Evolution. During this time, they were also an NSF iGERT Fellow and focused on projects such as optical control of stem cell differentiation and directed evolution of photoactivatable proteins and light emitting luciferases.
In 2017, Kamran joined Notable as a Senior Scientist, and later became the Head of Platform and Discovery in 2019. Their role at Notable involved leading the platform and discovery efforts in the company.
Kamran's most recent work experience is as the CTO and Co-founder of Eigen Therapeutics, a position they have held since 2022.
Kamran A. completed their undergraduate education at the University of California, Berkeley from 2005 to 2009. They earned a Bachelor of Arts degree with a major in Molecular Cell Biology during this time. Following their bachelor's degree, Kamran A. pursued further education at UC Irvine, where they enrolled as a PhD Candidate in Biomedical Engineering starting in 2010. They continued their studies at UC Irvine until 2017.
This person is not in any teams
This person is not in any offices
Eigen Therapeutics
Eigen Therapeutics is a biotechnology company on a mission to make therapies that make cancer easier to find and eliminate. Eigen is focused on the development of “priming” therapies, therapies that help targeted therapies reach their full potential by addressing cancer heterogeneity, making cancer cells more vulnerable and/or making healthycells more resilient to treatment. Eigen is building a high-throughput discovery platform to explore the space of priming therapies, leveraging proprietary machine learning algorithms to discover novel associations, new classes of drugs, and new potential therapies that change a cell's state to make it more vulnerable to a targeted therapy. The Eigen platform represents the intersection of biology and engineering, and includes robotic systems, laboratory operations software, and machine learning analysis pipelines—all developed in-house—with the ultimate goal of saving more lives.